Greenwich LifeSciences, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 31, 2023 and accepted by EDGAR at Mar 31, 2023, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-01-01 to 2022-12-31 | $6.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$8.0m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$7.8m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.61 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$6.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $7.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $13.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2022-12-31 | $13.5m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $262.9k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $262.9k | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $13.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-23-010284. Last ingested by Listed: Oct 26, 2026, 16:53 ET. Listed shows no prices and gives no investment advice.